3 research outputs found
Incidence and identification of risk factors for peripartum cardiomyopathy in adult pregnant women without a history of cardiac conditions
No full textLa miocardiopatía periparto es una enfermedad rara que afecta al 1.6% (31) de las mujeres embarazadas. Se caracteriza por disnea, congestión pulmonar, fatiga, ortopnea, edema en miembros inferiores, taquiarritmias y shock cardiogénico, cuando hay una descompensación sistémica. Los anteriormente mencionados generan grandes consecuencias en las pacientes luego del embarazo, alterando su calidad de vida e incluso aumentando la mortalidad. Objetivo. En este trabajo se plantea un protocolo para determinar la incidencia de miocardiopatía periparto en Los Cobos Medical Center en el año 2023. Metodología. Se realizará un estudio cuantitativo observacional de cohorte longitudinal prospectivo, en el que se evaluarán los cambios fisiológicos en cada trimestre de la gestación a través de Péptido Natriurético Atrial (ANP) y Ecocardiograma transtorácico. En una muestra de 448 mujeres gestantes previamente sanas, por medio del muestreo aleatorio o probabilístico, se evaluarán las diversas variables tanto modificables como no modificables que orientan a la identificación de los principales factores de riesgo que predisponen a esta patología, analizados con el programa Excel 365. Resultados esperados. Con el protocolo se busca identificar la incidencia y los factores de riesgo de la miocardiopatía periparto para diagnosticarla oportunamente y evitar las consecuencias a largo plazo, para así establecer un inicio en la investigación de cardiopatías en embarazo en la población colombiana, difundiendo esta información en congresos y posteriormente generar escalas de predicción. Conclusión. Se identificará la incidencia de miocardiopatías periparto en Los Cobos Medical Center en el año 2023, determinando el compromiso cardiovascular en consecuencia a los cambios fisiológicos de la gestaciónMédico CirujanoPregradoPeripartum cardiomyopathy is a rare disease that affects 1.6% (31) of pregnant women. It is characterized by dyspnea, pulmonary congestion, fatigue, orthopnea, edema in the lower limbs, tachyarrhythmias, and cardiogenic shock when there is systemic decompensation. The generate great consequences for patients after pregnancy, altering their quality of life and even increasing mortality. In this work, a protocol is proposed to determine the incidence of peripartum cardiomyopathy in Los Cobos Medical Center in the year 2023. Methodology. A quantitative observational prospective longitudinal cohort study will be carried out in which physiological changes will be evaluated in each trimester of the pregnancy through Atrial Natriuretic Peptide (ANF) and Transthoracic Echocardiogram. In a sample of 448 previously healthy pregnant women, through random or probabilistic sampling, we will evaluate both modifiable and non-modifiable variables that guide the identification of the main risk factors that predispose to this pathology, analyzed with the Excel 365 program. Expected results. The protocol seeks to identify the incidence and risk factors of peripartum myocardiopathy to diagnose the pathology promptly and avoid long-term consequences to establish a beginning in the investigation of heart disease during pregnancy in the Colombian population, by disseminating this information in conferences and subsequently generating prediction scales. Conclusion. The incidence of peripartum cardiomyopathies will be identified at Los Cobos Medical Center in the year 2023 determining the cardiovascular compromise because of the physiological changes of pregnancy
Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
No full textAbstract
Vγ9Vδ2 T cells, the main subset of γδ T lymphocytes in human peripheral blood, are endowed with antitumor functions such as cytotoxicity and IFNγ production. These functions are triggered upon T-cell receptor–dependent activation by non-peptidic prenyl pyrophosphates (“phosphoantigens”) that are selective agonists of Vγ9Vδ2 T cells, and which have been evaluated in clinical studies. Because phosphoantigens have shown interindividual variation in Vγ9Vδ2 T-cell activities, we asked whether metabolic resources, namely lipids such as cholesterol, could affect phosphoantigen-mediated Vγ9Vδ2 T-cell activation and function. We show here that Vγ9Vδ2 T cells express the LDL receptor upon activation and take up LDL cholesterol. Resulting changes, such as decreased mitochondrial mass and reduced ATP production, correlate with downregulation of Vγ9Vδ2 T-cell activation and functionality. In particular, the expression of IFNγ, NKG2D, and DNAM-1 were reduced upon LDL cholesterol treatment of phosphoantigen-expanded Vγ9Vδ2 T cells. As a result, their capacity to target breast cancer cells was compromised both in vitro and in an in vivo xenograft mouse model. Thus, this study describes the role of LDL cholesterol as an inhibitor of the antitumor functions of phosphoantigen-activated Vγ9Vδ2 T cells. Our observations have implications for therapeutic applications dependent on Vγ9Vδ2 T cells. Cancer Immunol Res; 6(4); 448–57. ©2018 AACR.</jats:p
Supplementary Figures 1-6 from Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
No full textS1. LDL-cholesterol does not affect the viability of human γÎ' T cells. S2. Effects of LDL-cholesterol on Vï�¤2+ T cells after 36 or 48 hours of culture. S3. Effects of LDL-cholesterol on additional immune functions of γÎ' T cells. S4. Effect of LDL-cholesterol on expanded Vγ9VÎ'2 T cells cultured in the presence of human plasma. S5. Effects of receptor blockade on breast cancer cell targeting by γÎ' T lymphocytes. S6: Cholesterol-rich diet reduces multifunctional anti-tumour γÎ' infiltrating lymphocytes.</p
